You are here

  • Home
  • Archive
  • Volume 11, Issue 12
  • Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential

 

Online download statistics by month:

Online download statistics by month: December 2023 to September 2025

AbstractFullPdf
Dec 2023468474144
Jan 202417017089
Feb 2024969651
Mar 2024929360
Apr 2024787950
May 2024616144
Jun 2024677234
Jul 2024687042
Aug 2024525627
Sep 2024606334
Oct 2024585954
Nov 2024616236
Dec 2024838443
Jan 2025646556
Feb 2025808038
Mar 2025686850
Apr 2025767841
May 2025656548
Jun 2025282917
Jul 2025110
Aug 2025110
Sep 2025110
Total17981827958